Trial · NCT07452913
Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
NCT07452913, Phase 4, Enrolling by invitation, Bahria University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes. Trials, record NCT07452913. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07452913
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
- NCT number
- NCT07452913
- Status
- Enrolling by invitation
- Phases
- Phase 4
- Enrollment
- 110 participants, estimated
- Lead sponsor
- Bahria University
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Metformin+ Empagliflozin + Sitagliptin, Metformin + Empagliflozin + Linagliptin
- First posted
- 2026-03-05
- Last updated
- 2026-03-05
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Outcome | 3 Months | Change in HbA1c levels in % |
| Secondary | Secondary Outcome : changes in weight from baseline to 12 weeks (kg) | 12 weeks | the study will measure percentage change in weight from baseline to 12 weeks and proportion of participants achieving weight loss 1- 3 kg as national institute of health. Time Frame: 12 weeks |
| Secondary | Secondary Outcome: changes in BMI from baseline to 12 weeks (kg/m²). | 12 weeks | The study will measure percentage changes in BMI from baseline to 12 weeks and proportion of participants achieving required BMI |
| Secondary | Secondary outcome: changes in lipid profile (TC, TG, HDL, LDL, VLDL) from baseline to 12 weeks (mg/dl) | 12 weeks | The study will measure the changes in lipid profiles level from baseline to 12 weeks to evaluate the efficacy of triple vs initial triple therapy |
| Secondary | Secondary Outcome: To measure safety of Adverse Effects (nausea, vomiting, diarrhea, constipation, UTIs, flu like symptoms, headache, hypoglycemia, weight gain) from baseline to 12 weeks | 12 weeks | The study will measure the safety of Adverse Effects (nausea, vomiting, diarrhea, constipation, UTIs, flu like symptoms, headache, hypoglycemia, weight gain) from baseline to 12 weeks to evaluate the safety of triple vs initial triple therapy |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07452913
GET https://conductscience.org/api/trials/v1/NCT07452913/registered